AUTHORS
Zak A Yaffe, MD, PhD, Emily C. Liang, MD2, Jennifer J. Huang, MD, PhD3, Yein Jeon, PhD4, Eashwar Somasundaram, MD5, Alexandre V Hirayama, MD6, Erik L Kimble, MD7, Andrew J. Portuguese, MD8, Aiko Torkelson, BS9, Delaney Kirchmeier, BS10, Mazyar Shadman, MD, MPH11, Brian G Till, MD12, David G Maloney, MD, PhD13, Stanley R Riddell, MD14, Cameron J. Turtle, MBBS, PhD15, Jordan Gauthier, MD16
AFFILIATIONS
1 Fred Hutch Cancer Center, Seattle, Washington, United States, University of Washington School of Medicine, Seattle, Washington, United States
2 Fred Hutch Cancer Center, Seattle, Washington, United States, University of Washington School of Medicine, Seattle, Washington, United States
3 Fred Hutch Cancer Center, Seattle, Washington, United States, University of Washington School of Medicine, Seattle, Washington, United States
4 Fred Hutch Cancer Center, Seattle, Washington, United States, University of Washington School of Medicine, Seattle, Washington, United States
5 Fred Hutch Cancer Center, Seattle, Washington, United States, University of Washington School of Medicine, Seattle, Washington, United States
6 Fred Hutch Cancer Center, Seattle, Washington, United States, University of Washington School of Medicine, Seattle, Washington, United States
7 Fred Hutch Cancer Center, Seattle, Washington, United States, University of Washington School of Medicine, Seattle, Washington, United States
8 Fred Hutch Cancer Center, Seattle, Washington, United States, University of Washington School of Medicine, Seattle, Washington, United States
9 Fred Hutch Cancer Center, Seattle, Washington, United States
10 Fred Hutch Cancer Center, Seattle, Washington, United States
11 Fred Hutch Cancer Center, Seattle, Washington, United States, University of Washington School of Medicine, Seattle, Washington, United States
12 Fred Hutch Cancer Center, Seattle, Washington, United States, University of Washington School of Medicine, Seattle, Washington, United States
13 Fred Hutch Cancer Center, Seattle, Washington, United States, University of Washington School of Medicine, Seattle, Washington, United States
14 Fred Hutch Cancer Center, Seattle, Washington, United States, University of Washington School of Medicine, Seattle, Washington, United States
15 Fred Hutch Cancer Center, Seattle, Washington, United States, Royal North Shore Hospital, Saint Leonards, New South Wales, Australia, The University of Sydney, Sydney, New South Wales, Australia
16 Fred Hutch Cancer Center, Seattle, Washington, United States, University of Washington School of Medicine, Seattle, Washington, United States
ABSTRACT
Introduction:
T-cells engineered with a murine CD19-targeted single-chain variable fragment (scFv)-containing chimeric antigen receptor (mCD19 CAR) have revolutionized the treatment of relapsed/refractory (R/R) large B-cell lymphomas (LBCL). However, they lack long-term anti-tumor efficacy in 60-70% of patients. Prior work from our group showed that mCD19 CAR T-cell expansion and persistence are blunted by endogenous CD8+ T-cell responses directed to murine scFv epitopes. This suggested fully human CD19 scFv-containing (hCD19) CAR T-cells may be less immunogenic, persist longer, and thus improve outcomes. However, whether hCD19 CAR T-cells outperform mCD19 CAR T cells in patients with R/R LBCL remains to date unknown. To address this critical gap, we retrospectively compared the outcomes of 120 patients with R/R LBCL beyond second line (3L+) treated at our center with investigational hCD19 CAR-T cells (n=19) or with the standard-of-care mCD19 CAR T-cell therapy lisocabtagene maraleucel (liso-cel, n=101) while adjusting for potential confounders.
Methods:
CD19 CAR-naïve patients with R/R LBCL treated with hCD19 CAR T-cells formulated at a 1:1 ratio of CD4+:CD8+ hCD19 CAR T-cells and administered at a dose of 2-7x106/kg on a phase I/II study (NCT03103971) were included. All CD19 CAR-naïve patients with R/R DLBCL who received standard-of-care or out-of-specification liso-cel were included. All patients had received at least 2 prior lines of lymphoma-directed therapy. Lymphodepletion (LD) included cyclophosphamide (Cy) 300 mg/m2/d and fludarabine (flu) 30 mg/m2/d for 3 days. Cytokine release syndrome (CRS) and immune effector cell-associated neurotoxicity syndrome (ICANS) were graded per ASTCT criteria. The covariate adjustment set in multivariable models was chosen to include potential measured confounders (including age, pre-LD LDH, number of prior therapies, presence of bulky disease) based on a causal diagram.
Results:
Pre-LD characteristics were comparable overall across cohorts: age (median 62 for hCD19 CAR T vs. 67 for liso-cel), gender (68% male vs. 60%), race (84% white vs. 78%), pre-LD LDH (median 197 vs. 170), presence of extra-nodal disease (84% vs. 62%), pre-LD largest lesion diameter (3.1cm vs. 2.6cm), prior number of systemic therapies (median 3 vs. 3), administration of bridging therapy after leukapheresis (47% vs. 61%). We observed a higher proportion of patients with bulky disease (largest lesion >5cm) in hCD19 recipients (53% vs. 20%, p = 0.008).
After hCD19 CAR T-cell therapy compared to liso-cel, we observed significantly higher rates of ICANS grade ≥1 (63% vs. 35%, p = 0.02), grade ≥2 (58% vs. 23%, p = 0.004), or grade ≥3 (42% vs. 14%, p = 0.008), and numerically higher rates and severity of CRS grade ≥1 (84% vs. 61%, p = 0.07), grade ≥2 (32% vs. 23%, p = 0.40). Overall (ORR) and complete response rates (CRR) by Lugano criteria were comparable between hCD19 CAR T and liso-cel at one-month post-infusion: 79% vs. 80% (p = 1.0) and 58% vs. 52% (p = 0.63), respectively. After a median follow-up of 24 months, hCD19 CAR and liso-cel patients had similar OS (74% vs. 59%; p=0.55) and PFS (42% vs 46%; p=0.39) rates. Among responders, there was a similar duration of response at 24 months (DOR; 47% vs. 55%; p = 0.27) between hCD19 CAR T and liso-cel.
In univariate regression analyses, hCD19 CAR T-cell therapy was associated with grade ≥3 ICANS (OR 4.66, p = 0.003). We did not find an impact of hCD19 CAR T-cell therapy on ORR (OR = 0.93, p = 0.90), CRR (OR = 1.30, p = 0.61), grade ≥2 CRS (OR = 1.57, p = 0.41), OS (HR = 0.79, p = 0.55), PFS (HR = 1.30, p = 0.39), or duration of response (HR = 1.50, p = 0.27). In multivariable regression models, hCD19 CAR T-cell therapy was associated with grade ≥3 ICANS (HR = 3.73, p = 0.04). We did not find an independent impact of the product type on ORR, CRR, grade 2+ CRS, OS, PFS, or DOR.
Conclusion:
We could not confirm superior anti-tumor efficacy after hCD19 CAR T-cell therapy compared to liso-cel in patients with 3L+ R/R LBCL, with both products achieving comparable rates of durable responses. We observed higher rates of toxicities after hCD19 CAR T, which could be related to differences in CAR T-cell dose or manufacturing, or higher disease bulk. Acknowledging potential residual confounding, our findings suggest the inclusion of a fully human instead of a murine CD19 scFv does not improve anti-tumor efficacy in CAR-naïve 3L+ R/R LBCL patients receiving Cy/flu LD.
DISCLOSURES
Zak A Yaffe, MD, PhD: No relevant conflicts of interest to declare.